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Hereditary tyrosinemia type I (tyrosinosis) is an 
autosomal recessive disorder of metabolism charac-
terized by a deficiency of fumarylacetoacetate hy-
drolase, resulting in the accumulation of abnormal 
metabolites of tyrosine that are toxic to both the 
liver and the kidney (1-3). Until the advent of liver 
transplantation, the only available treatment for this 
disease was dietary avoidance of aromatic amino 
acids and methionine. Although such therapy re-
sults in some symptomatic improvement, in none of 
the patients so treated is liver disease prevented, 
and in most, a relentless progression of the liver 
disease or the appearance of a hepatocellular carci-
noma (HCC) results in death within the first decade 
of life 0-5). 
Despite the fact that the National Institutes of 
Health consensus conference on liver transplanta-
tion in 1983 identified tyrosinemia as one of the 
metabolic diseases of the liver for which transplan-
tation is indicated and can produce a cure (6), there 
is still considerable confusion among pediatricians 
and surgeons as to when such patients should be 
referred for liver transplantation. In an attempt to 
answer this question, the outcome of 10 patients 
with tyrosinemia, who underwent orthotopic liver 
transplantation at the University of Pittsburgh, was 
reviewed. 
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CASE REPORTS 
Between January 1981 and December 1987, 1357 liver 
transplants were performed in 1043 patients at the Uni-
versity of Pittsburgh. Of these 1043, 689 were adults and 
354 were children. Eleven of these transplants were 
performed in 10 patients (nine females and one male) with 
tyrosinemia. Nine were children and one was a 21-
year-old adult (Table I). In each case, the diagnosis of 
tyrosinemia was based on the presence of characteristic 
clinical findings and was confirmed by the presence of 
elevated plasma and urinary tyrosine, phenylalanine, and 
methionine levels and the presence of increased levels of 
succinylacetone in the urine. Each subject had a mark-
edly increased alpha-fetoprotein level (range 2700-
180,000). 
All but one (OT 498) of these 10 patients had been 
maintained on a tyrosine-, phenylalanine-, and methion-
ine-restricted diet. This single patient was referred for 
transplantation without a trial of restrictive dietary man-
agement because of the presence of advanced liver dis-
ease at the time of her initial diagnosis. Six of the nine 
patients tolerated dietary restriction reasonably well but, 
while on the diet, developed progressive liver disease that 
necessitated liver transplantation. As can be seen from 
Table 1, these six patients were referred for liver trans-
plantation at a much older age than was the case for the 
three children who were not able to tolerate dietary 
management. 
RESULTS 
Of the 10 patients studied, seven are currently 
alive following liver transplantation with follow-ups 
ranging from 6 months to 6V2 years (Table 1). Of the 
three who died, the first, a I-month-old infant died 
as a result of a technical complication experienced 
during the transplant procedure (OT 991); the sec-
ond, who had bilateral chronic subdural hematomas 
prior to transplant surgery, dies as a result of 
bronchial aspiration six months after successful 
transplantation (OT 498); the third died of recurrent 
hepatocellular carcinoma five months after trans-
plantation (OT 454). 
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TABLE 1. CLINICAL AND PATHOLOGICAL FINDINGS IN 10 CASES REVIEWED 
Age in years 
at time of Tolerance of dietary 
OT* No. OLTx management Indications for transplant Hepatoma Dysplasia Current status 
206 29/12 good hepatoma yes yes alive 78 months 
after first 
transplant 
288 21 good acute liver failure after yes yes alive 56 months 
resection for hepatoma 
356 3 6/12 good chronic liver disease, yes yes alive 48 months 
suspected hepatoma 
400 3 good chronic liver disease yes yes alive 42 months 
454 6 good hepatoma yes yes died 5 months after 
transplant 
498 6/12 no dietary management progressive liver failure no yes died 6 months after 
transplant 
770 1 5/12 poor chronic liver disease no yes alive 21 months 
776 6/12 good progressive liver failure no yes alive 21 months 
991 1/12 poor acute liver failure no none died during surgery 
1107 1 poor chronic liver disease no yes alive 9 months 
*OT = Orthotopic liver transplantation. 
Of the seven surviving patients, six have normal 
liver function. One developed chronic rejection 
following a brief cessation of immunosuppression 
during a bout of pneumonitis due to pneumocystis. 
In Table 2 is shown the performance status of the 
seven surviving patients and their physical growth 
relative to the National Center of Health statistic 
percentiles. The surviving adult patient is working 
full-time, while the five children with good allograft 
function are performing well at school and are 
developing normally. The single child with chronic 
rejectiqn has experienced a decline in growth. 
All seven surviving patients had normal blood 
urea nitrogen (BUN) and creatinine levels before 
transplantation and have continued to maintain 
good posttransplant renal function (mean posttrans-
plant BUN of 18.4 mg ± 4.9 SD and creatinine of 
0.68 mg ± 0.36 SD. Comprehensive data demon-
strating the resolution of the clinical and metabolic 
features of tyrosinemia are available in four of the 
seven surviving patients (OT 206, 288, 356,400) and 
have been reported previously (7). All successfully 
transplanted patients have been maintained on an 
unrestricted diet. 
Three patients had clinically evident HCC prior 
to transplantation, which had been detected pre-
operatively as a result of frequent ultrasound mon-
itoring (Table 3). An attempted hepatic lobectomy 
in one of these patients led to acute liver failure (OT 
288). This patient had no residual carcinoma in the 
liver remnant at the time of transplantation and is 
currently alive 56 months following transplantation 
without any evidence of residual tumor. A second 
patient (OT 206) required a second transplant for 
TABLE 2. PERFORMANCE STATUS OF THE SURVIVING PATIENTS 
OT 
206 
288 
356 
400 
770 
776 
1107 
Preop height 
(percentile) 
25 
<5 
50 
90 
10 
10 
<5 
Preop weight 
(percentile) 
75 
<5 
10 
50 
<5 
25 
<5 
*LFTs = liver function tests. 
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Duration after 
transplant 
(months) 
78 
56 
48 
42 
21 
20 
9 
Height 
(percentile) 
90 
<5 
75 
95 
10 
<5 
25 
Weight 
(percentile) 
90 
<5 
90 
50 
<5 
<5 
25 
Observations 
Attending school normal LFTs* 
Transplanted at age 21, no 
further growth, working 
full-time 
Attending school, normal LFTs 
Attending school, normal LFTs 
Attending school, slow growth, 
Normal LFTs 
Chronic rejection, awaiting 
retransplantation 
Developing normally, normal 
LFTs 
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TABLE 3. PATHOLOGICAL FINDINGS IN 5 CASES WITH HCC 
OT Age Pathology 
Survival 
(months) 
206 29/12 Multifocal hepatomas involving both lobes of the liver measuring 
up to 2 em in greatest diameter 
78 
288 21 Large tumor involving most of the right lobe measuring up to \3 
em in greatest diameter; multiple satellite nodules containing 
tumor 
56 
356 36/12 Multifocal hepatoma in several nodules involving both lobes of the 
liver, measuring up to 2.5 em in greatest diameter 
48 
400 3 Multifocal hepatoma in several nodules involving both lobes 
measuring up to 2.5 em in greatest diameter 
42 
454 6 Large tumor involving 2/3 of the right lobe of the liver measuring 
up to II em in the larger diameter; multiple satellite nodules 
containing tumor and invasion of the portal vein and porta 
hepatis 
5 
graft rejection but is nonetheless alive 78 months 
following initial transplantation without evidence 
for residual cancer. The third patient (OT 454) had 
an extensive tumor in the right lobe, which was 
found to be invading the portal vein and, as a result, 
was given posttransplant chemotherapy. Despite 
the chemotherapy, he died of tumor recurrence five 
months after transplantation. Two additional pa-
tients (OT 356, OT 400) had HCC in their hepatec-
tomy specimens that were not detected during their 
pretransplant evaluations (Table 3). Both are cur-
rently alive and well 48 and 42 months following 
transplantation without any evidence of residual 
tumor. 
All five of the patients found to have HCC were 
>2 years of age. None of the patients <2 years of 
age had a HCC. However, all of the cases <2 years 
of age had cirrhosis and focal areas of hepatocellu-
lar dysplasia (small foci of hepatocytes with large 
hypochromatic nuclei) on histologic examination of 
their resected livers. 
DISCUSSION 
Liver transplantation for tyrosinemia was first 
performed in 1976 (8). Since then, there have been 
several such reports, each of which consists of a 
small number of cases (9-11). However, none have 
been as large as this series and none have addressed 
the issue of hepatocellular carcinoma and the timing 
of transplantation. 
Tyrosinemia presents in two different forms. In 
the acute form, symptoms appear within the first 
few months of life with vomiting, diarrhea, leth-
argy, hepatosplenomegaly, and failure to thrive. 
Although some of these patients with an acute onset 
improve, at least temporarily, with strict dietary 
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restriction, most die within the first year of life of 
progressive liver failure 0-5). Three of our patients 
(OT 498, 776, and 991) presented with the acute 
form of the disease with rapidly progressing liver 
failure. Two of these three survived the operation. 
Despite the fact that the incidence of technical 
complications of liver transplant surgery leading to 
a transplant mortality are great in children < 1 year 
of age 02, 13), the only opportunity for survival in 
such acute cases is liver replacement. Survival rates 
of 50-60% are obtained in this age group with 
transplantation and clearly justify performance of 
the procedure for this indication in such small 
children. 
In the chronic form of the disease, patients typi-
cally present with rickets and growth retardation. 
Evidence for liver disease in such cases is present in 
the form of ascites, jaundice, or a coagulopathy. 
Few such children reach adulthood, as did one of 
our patients (OT 288). The majority die during the 
first decade of life, either as a result of progressive 
liver disease or the development of a HCC (1-5). 
Dietary restriction in patients with the chronic form 
of the disease delays the onset of some of the 
clinical features of the disease and often allows 
these children to grow and survive beyond the first 
year of life. Since HCC does not appear to occur 
before the age of 2 years in children with tyrosine-
mia, liver transplantation should be offered to chil-
dren with tyrosinemia after 1 year of age, when 
transplant results are improved but before 3 years 
of age, when HCC is likely. Such an approach to 
transplantation would maximize transplant survival 
without the additional problem of HCC. 
Seven of our 10 patients present with the chronic 
form ofthe disease (OT 206, 288, 356, 400, 454, 770, 
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1107). Six are alive 9-78 months following trans-
plantation. Five have normal liver function; one has 
chronic rejection (OT 776). The single death in this 
group occurred as a result of recurrent HCC. This 
child was transplanted after 2 years of age. 
It is very encouraging to observe increased 
growth following transplantation in all but one of 
the surviving children. Three of the five children 
with good allograft function have shown marked 
increases in their percentile growth compared to 
their pretransplant levels (Table 2). Not surpris-
ingly, the single adult, and the only child with 
chronic rejection have not exhibited any posttrans-
plant growth acceleration. 
Van Thiel et al (7) and Flatmark et al (11) have 
demonstrated improvement in the renal tubular 
dysfunction of patients with tyrosinemia following 
liver transplantation. All seven surviving patients in 
this series, as in these two earlier series, have 
maintained good posttransplant renal function with 
mean BUN and creatinine levels of 18.4 mg/dl and 
0.68 mg/dl, respectively. Tuchman et al (9) and Van 
Thiel et al (7) have shown that mild metabolic 
abnormalities persist following liver transplantation 
and that these originate from extrahepatic tissues 
(probably the kidney) with residual fumaryl-
O-acetoacetate deficiency. The clinical significance 
of this finding is still to be elucidated but appears 
not to be a clinical problem, at least in the cases in 
this series, and probably reflects persistence of the 
tyrosinemia phenotype by the kidney. 
The incidence of HCC in tyrosinemia has been 
reported to be as high as 37% in patients who 
survive beyond the age of 2 years (5). The five 
patients with HCC in this series were all beyond the 
age of 2 years, the youngest being 33 months when 
the tumor was found. The association of tyrosine-
mia and hepatocellular dysplasia as well as hepato-
cellular carcinoma is of considerable interest. Hep-
atectomy specimens in nine of our 10 patients 
revealed histologic hepatocellular dysplasia charac-
terized as foci of hepatocytes with large hyperpig-
mented nuclei. It was impossible to correlate age 
and the degree of dysplasia because of variability of 
dysplasia not only in the same liver specimen but 
also within a given nodule. The high incidence of 
HCC in cases with tyrosinemia beyond the age of 2 
years and the probable progression of hepatocellu-
lar dysplasia to HCC early in the course of this 
disease after age 2 years but before age 3 years 
suggests that liver transplantation might be indi-
cated in all cases with the chronic form of the 
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disease and liver insufficiency beyond the age of 2 
years. 
Frequent alpha-fetoprotein determinations, he-
patic ultrasonograms, and liver biopsy are not with-
out risk and have not been routinely helpful in such 
cases. Alpha-fetoprotein levels can be elevated 
markedly in patients exhibiting dysplasia without 
evidence of carcinoma, as seen in four of the 
present cases. It is difficult to evaluate the clinical 
significance of nodular lesions found by repeated 
ultrasound examinations in a liver with cirrhosis. 
Moreover, there is a considerable sampling error in 
biopsying small nodular lesions in cirrhotic livers. 
One of our patients (OT 454) was followed prior to 
transplantation with periodic ultrasound examina-
tions. Despite such monitoring, at transplantation 
he was found to have an extensive tumor invading 
the portal vein. He died five months after transplant 
with recurrent HCC. When one considers the risk 
of death from HCC without OLTx after age 2 years 
and the current results with liver transplantation 
performed after age 1 year, serious consideration 
for early referral of patients with tyrosinemia for 
liver transplantation after 2 years of age appears 
advisable. 
SUMMARY 
Results of liver transplantation in 10 patients with 
tyrosinemia are reviewed. The indications for trans-
plantation were: hepatoma in three, acute liver 
failure in two, and progressive chronic liver disease 
in five. One patient died during surgery. Of the 
remaining nine who survived the operation, one 
died at six months as a result of bronchial aspiration 
and aspiration pneumonia, and a second trans-
planted for hepatoma died five months later with 
metastases. Seven patients are alive 6 months to 6Y2 
years following transplantation. Of these seven pa-
tients, six have normal liver function and a good 
performance status. One is awaiting retransplanta-
tion for chronic rejection. Hepatocellular carci-
noma (HCC) was found either preoperatively or 
incidentally in five patients, all older than 2 years at 
the time of their transplant. Four of these are alive 
and well without evidence of tumor with follow-ups 
between 3Y2 and 6Y2. Four of the five patients less 
than 2 years of age had hepatocellular dysplasia 
without evidence of carcinoma on histologic exam-
ination of the resected liver. This experience sug-
gests that liver transplantation should be considered 
seriously for children with hereditary tyrosinemia 
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who are more than 2 years of age because beyond 
that age the incidence of hepatocellular carcinoma 
(HCC) increases substantially. 
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